Search Result

Results for "

alzheimers

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) 5-HT Receptor (15) AAK1 (1) Acyltransferase (2) Adenosine Receptor (1) Adrenergic Receptor (5) Akt (4) Amino Acid Derivatives (3) AMPK (5) Amylases (1) Amyloid-β (127) Androgen Receptor (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (24) Autophagy (8) Bacterial (7) Beta-lactamase (1) Beta-secretase (30) Biochemical Assay Reagents (2) c-Fms (2) Calcium Channel (3) CaMK (1) Cannabinoid Receptor (1) Carbonic Anhydrase (4) Casein Kinase (7) Caspase (3) CCR (1) CDK (6) Cholinesterase (ChE) (167) COX (1) Cytochrome P450 (1) Dopamine Receptor (5) Dopamine Transporter (3) Drug Metabolite (2) DYRK (3) E1/E2/E3 Enzyme (2) EAAT (1) EGFR (2) Endogenous Metabolite (33) ERK (3) Farnesyl Transferase (1) Fat Mass and Obesity-associated Protein (FTO) (1) FKBP (1) Fluorescent Dye (3) GABA Receptor (1) Glucocorticoid Receptor (2) Glucosidase (3) GlyT (2) GnRH Receptor (1) GPR84 (1) GSK-3 (24) HBV (1) HDAC (6) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (7) Histone Acetyltransferase (2) Histone Methyltransferase (1) HIV (1) HSV (1) Huntingtin (1) IFNAR (1) iGluR (13) Insulin Receptor (2) Interleukin Related (4) Isotope-Labeled Compounds (11) JNK (6) Keap1-Nrf2 (10) Lipoxygenase (1) LPL Receptor (1) mAChR (11) MAGL (1) MAP3K (1) mGluR (2) MicroRNA (1) Microtubule/Tubulin (6) Mitochondrial Metabolism (4) MMP (3) Monoamine Oxidase (33) mTOR (2) nAChR (20) Neuropeptide Y Receptor (2) Neurotensin Receptor (1) NF-κB (6) NO Synthase (3) NOD-like Receptor (NLR) (3) Notch (2) Nuclear Factor of activated T Cells (NFAT) (1) Oxidative Phosphorylation (2) P-glycoprotein (3) p38 MAPK (3) p62 (2) PAI-1 (1) Parasite (1) Phosphatase (3) Phosphodiesterase (PDE) (9) Phospholipase (9) PI3K (1) Pim (1) PKC (1) Potassium Channel (3) PPAR (3) Prolyl Endopeptidase (PREP) (1) Prostaglandin Receptor (1) PROTACs (2) Proteasome (4) RAR/RXR (4) Ras (1) Reactive Oxygen Species (6) REV-ERB (1) RIP kinase (1) ROS Kinase (1) SARS-CoV (1) Serotonin Transporter (1) Sigma Receptor (4) Sirtuin (5) Somatostatin Receptor (3) STAT (2) Tau Protein (23) TGF-β Receptor (2) TNF Receptor (2) Toll-like Receptor (TLR) (1) Transthyretin (TTR) (1) Trk Receptor (1) Tyrosinase (1) VEGFR (1) Virus Protease (1) Wnt (3) α-synuclein (4) β-catenin (2) γ-secretase (26)
By Research Areas:	Cancer (57) Cardiovascular Disease (18) Endocrinology (12) Infection (11) Inflammation/Immunology (52) Metabolic Disease (33) Neurological Disease (612)
Click Chemistry:	Alkynes (4)

652

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13410

Xanomeline oxalate 1 Publications Verification LY246708 oxalate	mAChR	Neurological Disease
Xanomeline oxalate (LY246708 oxalate) is a potent and selective muscarinic receptor agonist (SMRA) and stimulates phosphoinositide hydrolysis in vivo. Xanomeline oxalate can be used for the research of Alzheimer’s disease .

HY-117259

Valiltramiprosate ALZ-801	Amyloid-β	Neurological Disease
ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound . ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease .

HY-P1060

LPYFD-NH2	Amyloid-β	Neurological Disease
LPYFD-NH2, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 can be used for the research of Alzheimer’s disease .

HY-P1060A

LPYFD-NH2 TFA	Amyloid-β	Neurological Disease
LPYFD-NH2 TFA, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 TFA can be used for the research of Alzheimer’s disease .

HY-P1362A

β-Amyloid (42-1), human TFA Amyloid β Peptide (42-1)(human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (42-1), human TFA is the inactive form of Amyloid β Peptide (1-42). β-Amyloid (42-1), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .

HY-P1051

β-Amyloid (12-28) Amyloid β-Protein (12-28)	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research .

HY-P1051A

β-Amyloid (12-28) (TFA) Amyloid β-Protein (12-28) (TFA); Amyloid Beta-Peptide (12-28) (human) TFA; β-Amyloid protein fragment(12-28) TFA	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (TFA) (Amyloid β-Protein (12-28) (TFA)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) (TFA) shows aggregation properties. β-Amyloid (12-28) (TFA) has the potential for Alzheimer’s disease research .

HY-162036

α-Amylase/α-Glucosidase-IN-7	Glucosidase Amylases Cholinesterase (ChE)	Neurological Disease Metabolic Disease
α-Amylase/α-Glucosidase-IN-7 (Compound 3f) is a competitive α-glucosidase and α-amylase enzyme inhibitor with IC₅₀ values of 18.52 and 20.25 µM, respectively. α-Amylase/α-Glucosidase-IN-7 can also effectively inhibit AChE and BChE, with IC₅₀ values of 9.25 and 10.06 µM respectively. α-Amylase/α-Glucosidase-IN-7 can be used in diabetes and Alzheimer’s research .

HY-150053

JNK-IN-11	JNK	Neurological Disease
JNK-IN-11 (compound 1) is a potent JNK inhibitor with an IC₅₀ value of 2.2, 21.4, 1.8 µM for JNK1, JNK2, JNK3, respectively. JNK-IN-11 has the potential for the research of alzheimer and parkinson disease .

HY-111263

NIAD-4	Amyloid-β	Neurological Disease
NIAD-4 is a fluorophore for optical imaging of amyloid-β (Aβ) in the central nervous system (CNS) for Alzheimer’s disease (AD). NIAD-4 binds to the same Aβ site with the binding affinity (K_i) of 10 nM .

HY-138935

Iclepertin BI-425809	GlyT	Neurological Disease
Iclepertin (BI-425809) is a potent, selective and orally active glycine transporter 1 (GlyT1) inhibitor. Iclepertin is inactive against GlyT2. Iclepertin can be used for Alzheimer disease and schizophrenia research .

HY-D0972

Thioflavine S 15+ Cited Publications Thioflavin S; Direct Yellow 7	Fluorescent Dye	Others
Thioflavine S is a fluorescent histochemical marker of dense core senile plaques. Thioflavine S can be used for Alzheimer's research .

HY-144762

K027	Cholinesterase (ChE)	Neurological Disease
K027 is a potent reactivator of Organophosphates (OP)-inhibited acetylcholinesterase (AChE). K027 can be used for the research of Alzheimer's disease .

HY-162258

AChE-IN-57	Cholinesterase (ChE)	Neurological Disease
AChE-IN-57 (compound 5b(SP-2)) is a potent AChE inhibitor. AChE-IN-57 improves cognitive defects. AChE-IN-57 restores the biochemical mediators and inhibits reactive oxygen and nitrogen species implicated in the neuroinflammation mechanism. AChE-IN-57 has the potential for the research of Alzheimer .

HY-131971

AChE/BChE-IN-1	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-1 is a potent and brain-penetrant dual inhibitor of Acetylcholinesterase and Butyrylcholinesterase, with IC₅₀s of 1.06 and 7.3 nM for hAChE and hBChE, respectively. AChE/BChE-IN-1 also has antioxidant activity. AChE/BChE-IN-1 can be used for the research of Alzheimer’s disease .

HY-132582

IONIS-MAPTRx BIIB080; ISIS 814907	Tau Protein	Neurological Disease
IONIS-MAPTRx (BIIB080) is the first Tau-lowering antisense oligonucleotide (ASO). IONIS-MAPTRx has the potential for the research of Alzheimer Disease .

HY-W027553

Ipidacrine	Cholinesterase (ChE)	Neurological Disease
2,3,5,6,7,8-Hexahydro-1H-cyclopenta[b]quinolin-9-amine is a pharmaceutically active compound which is a nootropic agent that acts as cholinesterase inhibitor and is used in research of Alzheimer disease .

HY-147060

Dyrk1A-IN-3	DYRK	Neurological Disease
Dyrk1A-IN-3 (Compound 8b), a highly selective dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor, maintains high levels of DYRK1A binding affinity (IC₅₀=76 nM). Dyrk1A-IN-3 can be used for the research of neurodegenerative disorders such as Alzheimer’s Disease, Huntington’s Disease, and Parkinson’s Disease .

HY-110176

ASP2535	GlyT	Neurological Disease
ASP2535 is a potent, orally bioavailable, selective, brain permeable and centrally-active glycine transporter-1 (GlyT1) inhibitor. ASP2535 can improve cognitive impairment in animal models of schizophrenia and Alzheimer's disease .

HY-N4206

Leptomerine	Cholinesterase (ChE)	Neurological Disease
Leptomerine, an alkaloid from stems of Esenbeckia leiocarpa Engl. (Rutaceae) as potential treatment for Alzheimer Disease. Leptomerine inhibits acetyl cholinesterase (AChE) with an IC₅₀ of 2.5 μM. Anticholinesterasic activity .

HY-108312A

AC-VEID-CHO TFA	Caspase	Neurological Disease
AC-VEID-CHO (TFA) is a peptide-derived caspase inhibitor and has potency of inhibition for Caspase-6, Caspase-3 and Caspase-7 with IC₅₀ values of 16.2 nM, 13.6 nM and 162.1 nM, respectively. AC-VEID-CHO (TFA) can be used for the research of neurodegenerative conditions including Alzheimer’s and Huntington’s disease .

HY-147962

AChE/HDAC-IN-1	Cholinesterase (ChE) HDAC	Neurological Disease
COX-2-IN-23 (compound A10) is a potent both AChE and HDAC inhibitor with IC₅₀ values of 0.12 and 0.23 nM. COX-2-IN-23 exhibits antioxidant activity and metal chelating properties. COX-2-IN-23 can be used in alzheimer's disease research .

HY-100550

MSDC 0160 2 Publications Verification Mitoglitazone; CAY10415	Insulin Receptor Mitochondrial Metabolism	Neurological Disease Endocrinology
MSDC 0160 (Mitoglitazone) is a mitochondrial target of thiazolidinediones (mTOT)-modulating insulin sensitizer and a modulator of mitochondrial pyruvate carrier (MPC). MSDC 0160 is a thiazolidinedione (TZD) with antidiabetic and neuroprotective activities. MSDC 0160 has the potential for Alzheimer′s disease .

HY-10933

CX516 1 Publications Verification BDP 12	iGluR	Neurological Disease
CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI) .

HY-N9854

Icariside E4	Potassium Channel	Inflammation/Immunology
Icariside E4 is an antinociceptive agent, and can be isolated from Tabebuia roseo-alba. Icariside E4 has peripheral analgesic activity by ATP-sensitive K ⁺ channel-dependent mechanisms. Icariside E4 also has anti-oxidant, anti-Alzheimer and anti-inflammatory effects .

HY-10096

TCS2002	GSK-3	Neurological Disease
TCS2002 (Compound 9b) is a highly selective, orally bioavailable and potent GSK-3β inhibitor with the IC₅₀ of 35 nM. TCS2002 shows good pharmacokinetic profiles including favorable BBB penetration. TCS2002 can be used for the research of Alzheimer’s disease .

HY-109052

Atabecestat JNJ-54861911	Beta-secretase	Neurological Disease
Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment .

HY-107529

TC-G 24	GSK-3	Neurological Disease Metabolic Disease
TC-G 24 (Compound 24) is a potent, selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC₅₀ of 17.1 nM. TC-G 24 can cross the BBB and can be used for studying many diseases such as type 2 diabetes mellitus, stroke, Alzheimer, and other related diseases .

HY-136736

β-Secretase Inhibitor II	Beta-secretase	Neurological Disease
β-Secretase Inhibitor II is a β-Secretase inhibitor. β-Secretase Inhibitor II is a simple tripeptide aldehyde (IC₅₀=700 nM for inhibition of total Aβ and IC₅₀=2.5 μM for Aβ_1–42). β-Secretase Inhibitor II can be used for the research of Alzheimer's disease .

HY-13779

(E/Z)-J147	Monoamine Oxidase Dopamine Transporter	Neurological Disease
(E/Z)-J147 is an exceptionally potent, orally active, neuroprotective agent for cognitive enhancement. (E/Z)-J147 can readily pass the blood brain barrier (BBB). (E/Z)-J147 can inhibit monoamine oxidase B (MAO B) and the dopamine transporter with EC₅₀ values of 1.88 μM and 0.649 μM, respectively. (E/Z)-J147 has potential for the treatment of Alzheimer’s disease (AD) .

HY-19651B

Zanapezil fumarate TAK-147 fumarate	Cholinesterase (ChE)	Neurological Disease
Zanapezil (TAK-147) fumarate is a potent, reversible and selective acetylcholine esterase (AChE) inhibitor. Zanapezil fumarate shows a potent and reversible inhibition of AChE activity in homogenates of the rat cerebral cortex (IC₅₀=51.2 nM). Zanapezil fumarate shows a moderate inhibition of muscarinic M1 and M2 receptor binding with K_i values of 234 and 340 nM, respectively. Zanapezil fumarate can be used for the research of early stages of Alzheimer's disease (AD) .

HY-117983

RU-505	Amyloid-β	Neurological Disease
RU-505 is an effective β-amyloid (Aβ)-fibrinogen interaction inhibitor with IC₅₀s of 5.00 and 2.72 μM in fluorescence polarization (FP) and AlphaLISA assays, respectively. RU-505 is highly permeable to the BBB. RU-505 reduces cerebral amyloid angiopathy (CAA). RU-505 can be used for the research of Alzheimer’s disease (AD) .

HY-151152

AChE-IN-24	Cholinesterase (ChE)	Neurological Disease
AChE-IN-24 is a potent AChE inhibitor and can penetrate the BBB. AChE-IN-24 has the mighty inhibitory activity to hAChE with an IC₅₀ value of 0.053 μM. AChE-IN-24 can be used for the research of Alzheimer s disease (AD) .

HY-145712

ElteN378	FKBP	Cancer
ElteN378 is an inhibitors of FKBP12e. ElteN378 can be used in study Alzheimer disease, Parkinson disease, Amyotrophic Lateral Sclerosis, proliferation disorders and cancer .

HY-19651

Zanapezil free base TAK-147 free base	Cholinesterase (ChE)	Neurological Disease
Zanapezil (TAK-147) free base is a potent, reversible and selective acetylcholine esterase (AChE) inhibitor. Zanapezil free base shows a potent and reversible inhibition of AChE activity in homogenates of the rat cerebral cortex (IC₅₀=51.2 nM). Zanapezil free base shows a moderate inhibition of muscarinic M1 and M2 receptor binding with K_i values of 234 and 340 nM, respectively. Zanapezil free base can be used for the research of early stages of Alzheimer's disease (AD) .

HY-10400

Ladostigil hemitartrate TV-3326 hemitartrate	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Ladostigil (TV-3326) hemitartrate is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hemitartrate exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil hemitartrate can be used for the research of depression and Alzheimer's disease . Ladostigil (hemitartrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P1061

Colivelin Maximum Cited Publications 34 Publications Verification	STAT Amyloid-β	Neurological Disease
Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury

HY-P1047

β-Sheet Breaker Peptide iAβ5 [Pro18, Asp21] β-Amyloid (17-21)	Amyloid-β	Neurological Disease
β-Sheet Breaker Peptide iAβ5 is a potent degrader of cerebral amyloid-beta (Abeta). Abeta deposition is associatied with the Alzheimer disease (AD), due to its related toxicity linked to its beta-sheet conformation and/or aggregation. β-Sheet Breaker Peptide iAβ5 reproducibly induces in vivo disassembly of fibrillar amyloid deposits. Thus, β-Sheet Breaker Peptide iAβ5 prevents and/or reverses neuronal shrinkage caused by Abeta, and reduces the extent of interleukin-1beta positive microglia-like cells that surround the Abeta deposits. β-Sheet Breaker Peptide iAβ5 reduces the size and/or number of cerebral amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 labeled by hydrophobic benzyl alcohol (HBA) tag, can be used for quantitative assay by showing vivid blue color under acidic conditions .

HY-P1061A

Colivelin TFA Maximum Cited Publications 34 Publications Verification	STAT Amyloid-β Apoptosis	Neurological Disease
Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury .

HY-117924

AUTEN-67 Autophagy enhancer-67	Autophagy	Neurological Disease
AUTEN-67 (Autophagy enhancer-67) is an orally active autophagy enhancer and MTMR14 inhibitor. AUTEN-67 has anti-aging and neuroprotective effects. AUTEN-67 protects neurons from stress-induced cell death. AUTEN-67 also restores nesting behavior in a mice model of Alzheimer disease .

HY-122487

Troriluzole BHV-4157	Others	Neurological Disease
Troriluzole, a third-generation, tripeptide proagent of Riluzole (HY-B0211), is an orally active glutamate modulator. Troriluzole reduces synaptic glutamate level and increases the synaptic glutamate absorption. Troriluzole has the potential for Alzheimer disease and generalized anxiety disorder (GAD) .

HY-144388

ChE/Aβ1-42-IN-1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
ChE/Aβ1-42-IN-1 (compound 28) is a potent ChE and Aβ_1-42 aggregation inhibitor with IC₅₀s of 0.062, 0.767 and 1.227 µM for AChE, BuChE and Aβ_1-42 aggregation, respectively. ChE/β1-42-IN-1 shows excellent BBB penetration. ChE/Aβ1-42-IN-1 is a potent multi-targeted anti-Alzheimer's agent .

HY-10399

Ladostigil TV-3326	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Ladostigil (TV-3326) is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease . Ladostigil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-144389

hAChE/Aβ1-42-IN-1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
hAChE/Aβ1-42-IN-1 (Compound 16) is a potent inhibitor of hAChE and Aβ1-42 aggregation. hAChE/Aβ1-42-IN-1 shows acceptable relative safety upon hepG2 cell line and excellent BBB penetration with wide safety margin. hAChE/Aβ1-42-IN-1 has the potential for the research of Alzheimer disease (AD) .

HY-10399A

Ladostigil hydrochloride TV-3326 hydrochloride	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Ladostigil (TV-3326) hydrochloride is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hydrochloride exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease . Ladostigil (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-130344

SKF 83959 1 Publications Verification	Dopamine Receptor Sigma Receptor	Neurological Disease
SKF83959 is a potent and selective dopamine D₁-like receptor partial agonist. SKF83959 K_i values for rat D₁, D₅, D₂ and D₃ receptors are 1.18, 7.56, 920 and 399 nM, respectively. SKF83959 is a potent allosteric modulator of sigma (σ)-1 receptor. SKF83959 belongs to benzazepine family and has improvements on cognitive dysfunction. SKF83959 can be used for the research of Alzheimer's disease and depression .

HY-103412

SKF 83959 hydrobromide 1 Publications Verification	Dopamine Receptor Sigma Receptor	Neurological Disease
SKF83959 hydrobromide is a potent and selective dopamine D₁-like receptor partial agonist. SKF83959 hydrobromide K_i values for rat D₁, D₅, D₂ and D₃ receptors are 1.18, 7.56, 920 and 399 nM, respectively. SKF83959 hydrobromide is a potent allosteric modulator of sigma (σ)-1 receptor. SKF83959 hydrobromide belongs to benzazepine family and has improvements on cognitive dysfunction. SKF83959 hydrobromide can be used for the research of Alzheimer's disease and depression .

HY-147011

FTO-IN-7	Fat Mass and Obesity-associated Protein (FTO)	Cancer
FTO-IN-7 is an inhibitor of FTO. FTO-IN-7 can be used in study Alzheimer's diseases, breast cancers, small-cell lung cancers,a human bone marrow striated muscle cancer, a pancreatic cancer, malignant glioblastoma .

HY-119173

PBD-150

Amyloid-β Neurological Disease

PBD-150 is a human glutaminyl cyclase (hQC) Y115E-Y117E variant inhibitor, with a K_i value of 490 nM .

HY-136813

Multitarget AD inhibitor-1	Beta-secretase Amyloid-β Cholinesterase (ChE)	Neurological Disease
Multitarget AD inhibitor-1 is a selective and reversible butyrylcholinesterase (BuChE) inhibitor with IC₅₀s of 7.22 μM and 1.55 μM for hBuChE and eqBuChE (BuChE from equine serum), respectively. Multitarget AD inhibitor-1 inhibits β-secretase (IC_50hBACE-1=41.60 μM), amyloid β aggregation (IC_50Aβ=3.09 μM), tau aggregation. Multitarget AD inhibitor-1, a diphenylpropylamine derivative, has the potential for multifunctional disease-modifying anti-Alzheimer’s research .

Cat. No.	Product Name

HY-L069

Anti-Alzheimer's Disease Compound Library

1374 compounds

Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc.

MCE offers a unique collection of 1374 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

HY-L028

CNS-Penetrant Compound Library

856 compounds

The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy.

MCE offers a unique collection of 856 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

HY-L068

Flavonoids Library

511 compounds

Flavonoids are an important class of natural products; particularly, they belong to a class of plant secondary metabolites having a polyphenolic structure, widely found in fruits, vegetables and certain beverages. Flavonoids can be subdivided into different subgroups depending on the carbon of the C ring on which the B ring is attached and the degree of unsaturation and oxidation of the C ring. These subgroups are: flavones, flavonols, flavanones, flavanonols, flavanols or catechins, anthocyanins and chalcones. Flavonoids are now considered as an indispensable component in a variety of nutraceutical, pharmaceutical, medicinal and cosmetic applications. This is attributed to their anti-oxidative, anti-inflammatory, anti-mutagenic and anti-carcinogenic properties coupled with their capacity to modulate key cellular enzyme function. Naturally occurring flavonoids are known to have biological activities for use as drugs, for example, in diseases like cancer, Alzheimer’s disease (AD), atherosclerosis, etc.

MCE offers a unique collection of 511 natural flavonoid compounds which is a useful tool for drug discovery as an important source of lead compounds.

HY-L070

Neuroprotective Compound Library

1058 compounds

Neurodegenerative diseases are characterised by progressive dysfunction and death of neurons, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS). Neuroprotection is an approach to preserve neurons so that neurons cannot be hurt by different pathological factors in neurodegenerative diseases. Neuroprotectors are some agonists and antagonists targeting some key targets in neuroprotactive signal pathways, such as calcium and sodium channel blockers, GABA receptor agonists, NMDA receptor Antagonists, etc. Current neuroprotectors cannot reverse existing damage, but they may protect against further nerve damage and slow down any degeneration of the central nervous system (CNS) and still play important roles in the treatment of neurodegenerative diseases.

MCE offers a unique collection of 1058 compounds with potential neuroprotective activities. These compounds mainly act on some key targets in neuroprotetive signal pathways, such as calcium channel, sodium channel, adenosine A1 receptor, etc. MCE Neuroprotective Compopund Library is a useful tool in neuroprotective drug discovery.

HY-L086

Neurodegenerative Disease-related Compound Library

2228 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 2228 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

HY-L134

Anti-Aging Natural Product Library

191 compounds

Aging is an unavoidable process, leading to cell senescence due to physiochemical changes in an organism. Aging cells cease to divide and drive the progression of illness through various pathways, resulting in the death of an organism ultimately. Anti-aging activities are primarily involved in the therapies of age-related disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), cardiovascular diseases, cancer, and chronic obstructive pulmonary diseases.

Natural products are known as effective molecules in anti-aging treatments, which delay the aging process through influencing several pathways and thus ensure an extended lifespan. MCE offers a unique collection of 191 natural products with validated anti-aging activity. MCE anti-aging natural product library is a useful tool for the study of aging-related diseases drugs and pharmacology.

HY-L003

Apoptosis Compound Library

2218 compounds

Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease.

MCE designs a unique collection of 2218 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

HY-L010

MAPK Compound Library

510 compounds

MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers.

MCE designs a unique collection of 510 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

HY-L034

Anti-Aging Compound Library

4352 compounds

Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.

MCE Anti-Aging Compound Library contains 4352 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

HY-L013

Neuronal Signaling Compound Library

2542 compounds

Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders.

MCE designs a unique collection of 2542 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

Cat. No.	Product Name	Target	Research Area

HY-P99185

Bapineuzumab	Amyloid-β	Neurological Disease
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .

HY-P99317

Solanezumab Immunoglobulin G1, anti-(human β-amyloid) (human-mouse monoclonAnti-Human Abeta Recombinant Antibody	Amyloid-β	Neurological Disease
Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab has the potential for the research of Alzheimer’s disease .

HY-P99471

Bepranemab UCB 0107	Tau Protein	Neurological Disease
Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research .

HY-P99648

Gosuranemab BMS-986168; IPN007; BIIB092	Tau Protein	Neurological Disease
Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .

HY-P99164

Zagotenemab LY33003560	Microtubule/Tubulin	Neurological Disease
Zagotenemab (LY3303560) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. Zagotenemab can be used in Alzheimer's disease research .

HY-P9967

Aducanumab BIIB037	Amyloid-β	Neurological Disease
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research .

HY-P99527

Vanutide cridificar ACC-001; PF 05236806	Inhibitory Antibodies	Neurological Disease
Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate. Vanutide cridificar can be used for Alzheimer's disease (AD) research .

HY-P99835

Crenezumab MABT 5102A; RG 7412	Amyloid-β	Neurological Disease
Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-Aβ monoclonal antibody that binds multiple forms of Aβ, such as soluble, oligomeric and fibrillar, for use in Alzheimer's disease research .

HY-P99022

Gantenerumab	Amyloid-β	Neurological Disease
Gantenerumab is a fully human anti-amyloid-β (Aβ) IgG1 monoclonal antibody demonstrates sustained cerebral amyloid-β binding. Gantenerumab can be used for Alzheimer's disease research .

HY-P99859

Donanemab LY3002813	Amyloid-β	Neurological Disease
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .

HY-P99216

Ponezumab PF-04360365; RN 1219	EGFR	Neurological Disease
Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease .

HY-P9999

Trontinemab RG6102; RO-7126209	Amyloid-β	Neurological Disease
Trontinemab is a bispecific and humanizedized IgG1-κ antibody, targeting to amyloid beta A4 precursor protein (APP) and transferrin receptor, p90, CD71 (TFRC). Trontinemab can be used for research on Alzheimer disease (AD) .

HY-P99399

Semorinemab RG 6100; RO7105705; MTAU-9937A	Tau Protein	Neurological Disease
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a K_d value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .

HY-P99163

Tilavonemab ABBV-8E12; C2N-8E12	Microtubule/Tubulin	Neurological Disease
Tilavonemab (ABBV-8E12) is a humanised anti-tau antibody that binds amino acids 25-30 near the N-terminal end of the tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates and reduces brain atrophy. Tilavonemab can be used in the study of Alzheimer's disease .

HY-P99407

Pepinemab VX 15/2503	Inhibitory Antibodies	Neurological Disease
Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W015229

3-Indolepropionic acid 2 Publications Verification Indole-3-propionic acid; 3-IPA	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite Reactive Oxygen Species
3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease.

HY-N4206

Leptomerine	Alkaloids other families Source classification Quinoline Alkaloids Plants	Cholinesterase (ChE)
Leptomerine, an alkaloid from stems of Esenbeckia leiocarpa Engl. (Rutaceae) as potential treatment for Alzheimer Disease. Leptomerine inhibits acetyl cholinesterase (AChE) with an IC₅₀ of 2.5 μM. Anticholinesterasic activity .

HY-N9854

Icariside E4	Tabebuia roseoalba (Ridl.) Sandwith Structural Classification Natural Products Source classification Plants Bignoniaceae	Potassium Channel
Icariside E4 is an antinociceptive agent, and can be isolated from Tabebuia roseo-alba. Icariside E4 has peripheral analgesic activity by ATP-sensitive K ⁺ channel-dependent mechanisms. Icariside E4 also has anti-oxidant, anti-Alzheimer and anti-inflammatory effects .

HY-N8414

Dehydrogeijerin	Structural Classification Natural Products Euryops arabicus Steud. ex Jaub. & Spach Source classification Plants Umbelliferae	Cholinesterase (ChE)
Dehydrogeijerin is an inhibitor of acetylcholinesterase with an IC₅₀ of 9.7 μM. Dehydrogeijerin can be used in study Alzheimer’s disease .

HY-130750

Phycocyanobilin	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification	Reactive Oxygen Species
Phycocyanobilin, an orally active antioxidative agent, is an effective scavenger for various reactive oxygen species. Phycocyanobilin can be used for the research of Alzheimer’s disease .

HY-119398

Lanuginosine	Structural Classification Alkaloids Fissistigma polyanthum (Hook. f. et Thoms.) Merr. Source classification Plants Annonaceae Isoquinoline Alkaloids	Amyloid-β Cholinesterase (ChE)
Lanuginosine (Compound 12) is an AChE inhibitor (IC₅₀: 10.9 μM). Lanuginosine inhibits Aβ aggregation. Lanuginosine can be used for research of Alzheimer’s disease .

HY-N8376

Fustin (±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone	Flavanonols Flavonoids Source classification Plants Rhus glabra L. Anacardiaceae	Amyloid-β mAChR Cholinesterase (ChE)
Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) is a potent amyloid β (Aβ) inhibitor. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases the expression of acetylcholine (ACh) levels, choline acetyltransferase (ChAT) activity, and ChAT gene induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) decreases in acetyl cholinesterase (AChE) activity and AChE gene expression induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases muscarinic M1 receptor gene expression and muscarinic M1 receptor binding activity. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) can be used for Alzheimer's disease research .

HY-122957

Huperzine C	Lycopodiaceae Alkaloids Lycopodium serratum Thunb． Source classification Plants	Cholinesterase (ChE)
Huperzine C is an alkaloid isolated from Huperzia serrate. Huperzine C is an acetylcholinesterase (AChE) inhibotor, with an IC₅₀ of 0.6 μM. Huperzine C can be used for the research of Alzheimer’s disease .

HY-N12075

Dehydrodiscretamine chloride	Structural Classification Alkaloids Piperidine Alkaloids Nandina domestica Thunb. Fissistigma polyanthum (Hook. f. et Thoms.) Merr. Source classification Plants Annonaceae Berberidaceae	Cholinesterase (ChE)
Dehydrodiscretamine chloride is a dual inhibitor of AChE and BChE with IC₅₀s of 17.8 and 118.8 μM, respectively. Dehydrodiscretamine chloride has antioxidant activity. Dehydrodiscretamine chloride can be used in study Alzheimer’s disease .

HY-N8453

Macranthoin G Methyl 3,5-dicaffeoyl quinic acid	Structural Classification Caprifoliaceae Lonicera japonica Thunb. Source classification Phenols Polyphenols Plants	p38 MAPK
Macranthoin G is an inhibitor of p38 MAPK. Macranthoin G protects the cytotoxicity induced by Aβ or hydrogen peroxide in neuronal cells by downregulating p38 MAPK. Macranthoin G can used in study Alzheimer’s Disease .

HY-N7046

Silybin B Silibinin B	Flavanonols Structural Classification Flavonoids Glycine soya Source classification Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae	Amyloid-β
Silybin B, a flavonolignan separated from Silybum marianum, has anti-tumor activity. Silybin B is the most potent antifibrillogenic and anti-oligomeric component of silymarin and proposes it as a promising anti Alzheimer’s disease agent candidate .

HY-N0804A

Isonaringin	Citrus × aurantium Linnaeus Flavonoids Flavonones Source classification Rutaceae Phenols Polyphenols Plants	Cholinesterase (ChE)
Isonaringin shows anti-Alzheimer’s activity by inhibiting AChE .

HY-N12027

AChE/BChE-IN-14	Structural Classification Alkaloids Fissistigma polyanthum (Hook. f. et Thoms.) Merr. Source classification Plants Annonaceae Isoquinoline Alkaloids	Cholinesterase (ChE)
AChE/BChE-IN-14 (compound 13) is a benzylisoquinoline alkaloid isolated from the roots of Fissistigma polyanthum. AChE/BChE-IN-14 exhibits AChE and BChE inhibitions with antioxidant activities. AChE/BChE-IN-14 can be used for Alzheimer’s disease research .

HY-W742564

Acacetin-7-O-β-D-galactopyranoside	Structural Classification Flavonoids Flavones Source classification Dendranthema morifolium (Ramat.) Tzvel. Plants Compositae	Cholinesterase (ChE)
Acacetin-7-O-β-D-galactopyranoside is a flavonoid that can be isolated from flower heads of Chrysanthemum morifolium. Acacetin-7-O-β-D-galactopyranoside inhibits AChE activity and can be used for research of Alzheimer’s disease .

HY-N12581

Kuwanon U	Structural Classification Flavonoids Flavonones Source classification Morus alba L. Plants Moraceae	Cholinesterase (ChE)
Kuwanon U is a potent cholinesterase inhibitor with IC₅₀s of 19.69, 10.11 µM and K_is of 6.48, 9.59 µM for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively. Kuwanon U has the potential for the research of Alzheimer’s disease (AD) .

HY-N2898

Artanin	Source classification Rutaceae Zanthoxylum nitidum (Roxb.) DC. Coumarins Phenylpropanoids Plants	Cholinesterase (ChE)
Artanin is a coumarin, has biological activities related to Alzheimer’s disease. Artanin exerts function including AChE inhibitory and AChE- and self-induced amyloid beta (Aβ) aggregation inhibitory activities, with IC₅₀s of 51 μM, 98 μM, and 124 μM, respectively .

HY-N7954

Neopanaxadiol	Panax ginseng C. A. Meyer Triterpenes Terpenoids Source classification Plants Araliaceae	Others
Neopanaxadiol, an aglycone of protopanaxadiol type ginsenosides, has the potential for Alzheimer's disease research .

HY-N8755

Chikusetsusaponin Ib	Triterpenes other families Terpenoids Source classification Plants	Cholinesterase (ChE)
Chikusetsusaponin Ib has anti-Alzheimer's disease activity and is a potent AChE inhibitor .

HY-N3963

Gomisin M2 (+)-Gomisin M2	Classification of Application Fields Neurological Disease Source classification Lignans Plants Infection Monophenols Phenols Phenylpropanoids Schisandraceae Disease Research Fields Inflammation/Immunology Schisandra chinensis (Turcz.) Baill.	HIV
Gomisin M2 ((+)-Gomisin M2) is a lignan isolated from the fruits of Schisandra rubriflora with anti-HIV activity (EC₅₀ of 2.4 μM). Gomisin M2 exhibits anti-cancer and anti-allergic activities and has the potential for Alzheimer’s disease research .

HY-N11641

Methyl ganoderate A acetonide	Triterpenes Structural Classification Microorganisms Terpenoids Source classification	Cholinesterase (ChE)
Methyl ganoderate A acetonide, a lanostane triterpene, is a natural product that could be isolated from the fruiting bodies of Ganoderma lucidum. Methyl ganoderate A acetonide is a potent AChE inhibitor with an IC₅₀ value of 18.35 μM. Methyl ganoderate A acetonide can be used in research of Alzheimer’s disease (AD) .

HY-125125

Danshenxinkun D	Quinones Structural Classification Terpenoids Labiatae Source classification Samanea saman (Jacq.) Merr. Diterpenoids Plants Phenanthrenequinones	Others
Danshenxinkun D is an anti-Alzheimer's disease (AD) candidate. Danshenxinkun D can significantly reverse the expression of PSEN1 and DRD2 mRNA in H₂O₂ treated PC12 cells. Danshenxinkun D can be used in the study of anti-Alzheimer's disease product candidate [1].

HY-N4005

Isoastilbin	Flavanonols Flavonoids other families Source classification Phenols Polyphenols Plants	Bacterial Tyrosinase
Isoastilbin is a dihydroflavonol glycoside compound in Rhizoma Smilacis glabrae and Astragalus membranaceus. Isoastilbin inhibits glucosyltransferase (GTase) with an IC₅₀ value of 54.3 μg/mL, and also inhibits tyrosinase activity. Isoastilbin shows neuroprotective, antioxidation, antimicrobial and anti-apoptotic properties and has the potential for Alzheimer’s disease research .

HY-P0265

β-Amyloid (1-40)	Structural Classification Natural Products Source classification Endogenous metabolite	Amyloid-β
β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease.

HY-N5077

Sinapine 2 Publications Verification	Alkaloids Structural Classification Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Cruciferae Source classification Phenols Plants Inflammation/Immunology Disease Research Fields	Cholinesterase (ChE) P-glycoprotein
Sinapine is an alkaloid isolated from seeds of the cruciferous species. Sinapine exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease .

HY-N10701

AChE/BChE-IN-11	Structural Classification Oleaceae Syringa oblata Lindl. Source classification Plants Saccharides Monosaccharides	Cholinesterase (ChE)
AChE/BChE-IN-11 (compound 1) is a potent is a dual AChE and BChE inhibitor with IC₅₀ values of 70 and 71 μM for AChE and BChE, respectively. AChE/BChE-IN-11 is a natural product that could be isolated from the leaf of artichoke . AChE/BChE-IN-11 can be used in research of Alzheimer’s disease (AD) research .

HY-N0450

Sinapine thiocyanate 2 Publications Verification	Alkaloids Structural Classification Monophenols Classification of Application Fields Cruciferae Source classification Phenols Plants Disease Research Fields Cancer	P-glycoprotein Cholinesterase (ChE)
Sinapine thiocyanate is an alkaloid isolated from seeds of the cruciferous species. Sinapine thiocyanate exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine thiocyanate is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease .

HY-123033A

Nicotinamide riboside chloride 5+ Cited Publications	Alkaloids Structural Classification Animals Neurological Disease Classification of Application Fields Anti-aging Source classification Pyridine Alkaloids Metabolic Disease Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside Chloride, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033

Nicotinamide riboside	Natural Products Human Gut Microbiota Metabolites Microorganisms Animals Neurological Disease Classification of Application Fields Anti-aging Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-N5077B

Sinapine hydroxide	Alkaloids Monophenols other families Classification of Application Fields Neurological Disease Source classification Phenols Plants Disease Research Fields Inflammation/Immunology	Cholinesterase (ChE) P-glycoprotein
Sinapine hydroxide is an alkaloid isolated from seeds of the cruciferous species. Sinapine hydroxide exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine hydroxide is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease .

HY-B1804

Tricaprilin Trioctanoin; Glyceryl trioctanoate	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Tricaprilin (Trioctanoin) is used in study for patients with mild to moderate Alzheimer's disease and has a role as an anticonvulsant and a plant metabolite .

HY-N12038

Coumarinic acid	Structural Classification Monophenols Microorganisms Ketones, Aldehydes, Acids Source classification Phenols	Amyloid-β Cholinesterase (ChE)
Coumarinic acid is a brain-penetrating inhibitor of AChE and β-amyloid. Coumarinic acid can be used in study anti-Alzheimer drug .

HY-N0690

Schisandrin C 4 Publications Verification Schizandrin-C; Wuweizisu-C	Structural Classification Classification of Application Fields Source classification Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Disease Research Fields Cancer	Apoptosis Virus Protease
Schisandrin C (Schizandrin-C) is a phytochemical lignan isolated from Schizandra chinensis . Schisandrin C has diverse biological activities, including anticancer, anti-inflammatory and antioxidant effects. Schisandrin C is a molecular glue. Schisandrin C can be used for cancer, alzheimer’s disease, and liver diseases research . Schisandrin C induces cell apoptosis .

HY-N6906

Oleuroside 1 Publications Verification	Iridoids Canarium album (Lour.) Rauesch. Terpenoids Source classification Phenols Polyphenols Plants Burseraceae	Others
Oleuroside is a phenolic secoiridoid in olive. Oleuroside can protect against mitochondrial dysfunction in models of early Alzheimer's disease and brain ageing .

HY-N7751

Isotanshinone II	Structural Classification Terpenoids Labiatae Source classification Diterpenoids Plants Salvia glutinosa L.	Others
Isotanshinone II is a natural product that can be isolated from Salvia glutinos. Isotanshinone II can be used to study Alzheimer's disease .

HY-17387

(-)-Huperzine A 3 Publications Verification Huperzine A	Structural Classification Neurological Disease Classification of Application Fields Anti-aging Huperziaceae Source classification Pyridine Alkaloids Plants Alkaloids Terpenoids Sesquiterpenes Huperzia serrata Disease Research Fields	Cholinesterase (ChE) Apoptosis iGluR
(-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC₅₀ of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease .

HY-123033B

Nicotinamide riboside tartrate	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside tartrate, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside tartrate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside tartrate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033C

Nicotinamide riboside malate	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside malate, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside malate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside malate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-N0785

Ginkgolide C BN-52022; Ginkgolide-C	Ginkgoaceae Terpenoids Source classification Diterpenoids Plants Endogenous metabolite Ginkgo biloba	AMPK Sirtuin MMP Endogenous Metabolite
Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease.

HY-N8260

Angeloylgomisin Q	Source classification Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill.	Others
Angeloylgomisin Q is a new dibenzocyclooctadiene lignan from the stems of Schisandra sphaerandra . Angeloylgomisin Q has the potential for alzheimer's disease research .

HY-N2807

Acanthoside B	Monophenols Cistanche salsa (C. A. Mey.) G. Beck Source classification Lignans Phenols Orobanchaceae Phenylpropanoids Plants	Others
Acanthoside B is a potential bioactive lignan with anti-inflammatory and anti-amnesic activities. Acanthoside B can be used for alzheimer's disease and lung inflammation research

HY-B1328

Pyridoxine 5 Publications Verification Pyridoxol	Structural Classification Natural Products Microorganisms Source classification Disease markers Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder	Endogenous Metabolite Keap1-Nrf2
Pyridoxine (Pyridoxol) is a pyridine derivative. Pyridoxine exerts antioxidant effects in cell model of Alzheimer's disease via the Nrf-2/HO-1 pathway.

HY-W040141

L-Arabinitol	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Disease markers Metabolic Disease Endocrine diseases Endogenous metabolite Disease Research Fields Saccharides	Endogenous Metabolite
L-Arabinitol is a potential biomarker for the comsuption of the food products such as sweet potato, deerberry, moth bean, and is also associated with Alzheimer's disease and ribose-5-phosphate isomerase deficiency.

HY-N12423

Bis-(-)-8-demethylmaritidine	Crinum asiaticum L. Structural Classification Alkaloids Other Alkaloids Source classification Plants Amaryllidaceae	Cholinesterase (ChE)
Bis-(-)-8-demethylmaritidine, a natural alkaloid, is a potent acetylcholinesterase (AChE) inhibitor. Bis-(-)-8-demethylmaritidine can be used for Alzheimer's disease research .

HY-N7480A

Quinolactacin A1	Alkaloids Microorganisms Pyrrole Alkaloids Classification of Application Fields Neurological Disease Source classification Quinoline Alkaloids Disease Research Fields	Cholinesterase (ChE)
Quinolactacin A1 is a potent acetylcholinesterase (AChE) inhibitor from solid state fermentation of Penicillium citrinum 90648. Quinolactacin A1 can be used for the research of Alzheimer disease .

HY-N8728

Aposcopolamine	Structural Classification Alkaloids Source classification Plants Solanaceae Duboisia leichhardtii (F.Muell.) F.Muell.	Cholinesterase (ChE) Adrenergic Receptor
Aposcopolamine is an alkaloid that can be isolated from Datura ferox. Aposcopolamin can closely binds with ACHE, ADRA2A and CHRM2. Aposcopolamine can be used for the research of Alzheimer's disease .

HY-17388

(±)-Huperzine A 1 Publications Verification	Structural Classification Terpenoids Huperziaceae Sesquiterpenes Source classification Huperzia serrata Plants	Cholinesterase (ChE)
(±)-Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD).

HY-N2043

Huperzine B	Lycopodiaceae Alkaloids Piperidine Alkaloids Lycopodium serratum Thunb． Source classification Pyridine Alkaloids Plants	Cholinesterase (ChE)
Huperzine B is a Lycopodium alkaloid isolated from Huperzia serrata and a highly selective acetylcholinesterase (AChE) inhibitor. Huperzine B can be uesd to can be used to improve Alzheimer's disease .

HY-113303

FAPy-adenine	Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
FAPy-adenine is an oxidized DNA base. Fapy-adenine shows an increased trend levels in the Alzheimer's disease brain. Oxidized nucleosides are biochemical markers for tumors, aging, and neurodegenerative diseases .

HY-122381

Kyotorphin	Structural Classification Monophenols Neurological Disease Classification of Application Fields Source classification Phenols Endogenous metabolite Disease Research Fields	Bacterial Endogenous Metabolite
Kyotorphin is an endogenou neuroactive dipeptide with analgesic properties. Kyotorphin possesses anti-inflammatory and antimicrobial activity. Kyotorphin levels in cerebro-spinal fluid correlate negatively with the progression of neurodegeneration in Alzheimer's Disease patients .

HY-N10487

Bleformin A	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Source classification Polyphenols Plants	Cholinesterase (ChE)
Bleformin A is a potent BChE inhibitor with an IC₅₀ value of 5.2 μM. Bleformin A is a nature product that could be isolated from Bletilla striata. Bleformin A can be used for research of Alzheimer's disease (AD) .

Cat. No.	Product Name	Chemical Structure

HY-W015229S

3-Indolepropionic acid-d2
3-Indolepropionic acid-d₂ is the deuterium labeled 3-Indolepropionic acid. 3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease.

HY-B1804S1

Tricaprilin-d50
Tricaprilin-d₅₀ is the deuterium labeled Tricaprilin. Tricaprilin (Trioctanoin) is used in study for patients with mild to moderate Alzheimer's disease and has a role as an anticonvulsant and a plant metabolite[1][2].

HY-B1804S2

Tricaprilin-d15
Tricaprilin-d₁₅ is the deuterium labeled Tricaprilin. Tricaprilin (Trioctanoin) is used in study for patients with mild to moderate Alzheimer's disease and has a role as an anticonvulsant and a plant metabolite[1][2].

HY-B1328S1

Pyridoxine-d3
Pyridoxine-d3 is a deuterium labeled Pyridoxine. Pyridoxine (Pyridoxol) is a pyridine derivative. Pyridoxine exerts antioxidant effects in cell model of Alzheimer's disease via the Nrf-2/HO-1 pathway .

HY-N0682S1

Pyridoxine-d2 hydrochloride
Pyridoxine-d₂ (hydrochloride) is the deuterium labeled Pyridoxine hydrochloride. Pyridoxine hydrochloride is a pyridine derivative. Pyridoxine (Pyridoxol; Vitamin B6) exerts antioxidant effects in cell model of Alzheimer's disease via the Nrf-2/HO-1 pathway.

HY-10933S

CX516-d10
CX516-d₁₀ is the deuterium labeled CX516. CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI)[1].

HY-P0265AS

β-Amyloid-15N (1-40) (TFA)
β-Amyloid- ¹⁵N (1-40) (TFA) is the ¹⁵N-labledβ-Amyloid (1-40) (TFA). β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease[1].

HY-N0682S

Pyridoxine-d3 hydrochloride
Pyridoxine-d₃ (hydrochloride) is the deuterium labeled Pyridoxine hydrochloride. Pyridoxine hydrochloride (Pyridoxol; Vitamin B6) is a pyridine derivative. Pyridoxine (Pyridoxol; Vitamin B6) exerts antioxidant effects in cell model of Alzheimer's disease via the Nrf-2/HO-1 pathway.

HY-B1328S

Pyridoxine-d5
Pyridoxine-d₅ (Pyridoxol-d₅) is a deuterium labeled Pyridoxine (HY-B1328). Pyridoxine (Pyridoxol) is a pyridine derivative. Pyridoxine exerts antioxidant effects in cell model of Alzheimer's disease via the Nrf-2/HO-1 pathway.

HY-N0682S3

Pyridoxine-13C4 hydrochloride
Pyridoxine- ¹³C₄ (hydrochloride) is the ¹³C-labeled Pyridoxine (hydrochloride). Pyridoxine hydrochloride (Pyridoxol; Vitamin B6) is a pyridine derivative. Pyridoxine (Pyridoxol; Vitamin B6) exerts antioxidant effects in cell model of Alzheimer's disease via the Nrf-2/HO-1 pathway.

HY-N0682S2

Pyridoxine-d5 hydrochloride
Pyridoxine-d₅ (hydrochloride) is the deuterium labeled Pyridoxine hydrochloride[1]. Pyridoxine hydrochloride (Pyridoxol;Vitamin B6) is a pyridine derivative. Pyridoxine (Pyridoxol;Vitamin B6) exerts antioxidant effects in cell model of Alzheimer's disease via the Nrf-2/HO-1 pathway[2].

HY-N6608S

Physostigmine-d3

Physostigmine-d₃ is the deuterium labeled Physostigmine. Physostigmine (Eserine) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine can crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine is also an antidote for anticholinergic poisoning[1][2][3][4].

HY-113354S

Anserine-d4

Anserine-d₄ is the deuterium labeled Anserine. Anserine, a methylated form of Carnosine, is an orally active, natural Histidine-containing dipeptide found in skeletal muscle of vertebrates. Anserine is not cleaved by serum carnosinase and act as biochemical buffers, chelators, antioxidants, and anti-glycation agents. Anserine improves memory functions in Alzheimer's disease (AD)-model mice[1][2].

HY-B0702S

Nicergoline-13C,d3
Nicergoline- ¹³C,d₃ is the ¹³C- and deuterium labeled Nicergoline. Nicergoline, an ergoline derivative ester of bromonicotinic acid, is a potent, selective and orally active antagonist of α1A-adrenoceptor. Nicergoline has vasodilator effects. Nicergoline also has ameliorative effects on cognitive function in mouse models of Alzheimer's disease[1][2].

HY-P1363S

β-Amyloid-15N (1-42), human TFA
β-Amyloid- ¹⁵N (1-42), human (TFA) is the ¹⁵N-labledβ-Amyloid (1-42) (TFA). β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease[1].

HY-F0004S

β-Nicotinamide mononucleotide-d4

β-Nicotinamide mononucleotide-d₄ is the deuterium labeled β-Nicotinamide mononucleotide. β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity[1].

HY-113354S1

Anserine-d4 hydrochloride

Anserine-d₄ hydrochloride is the deuterium labeled Anserine (HY-113354). Anserine, a methylated form of Carnosine, is an orally active, natural Histidine-containing dipeptide found in skeletal muscle of vertebrates. Anserine is not cleaved by serum carnosinase and act as biochemical buffers, chelators, antioxidants, and anti-glycation agents. Anserine improves memory functions in Alzheimer's disease (AD)-model mice .

HY-B1028S

Pantethine-15N2

Pantethine- ¹⁵N₂ is the ¹⁵N₂ labeled Pantethine. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .

HY-17368S1

(rac)-Rivastigmine-d6

(rac)-Rivastigmine-d₆ is a labelled racemic Rivastigmine. Rivastigmine (S-Rivastigmine) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease[1][2].

HY-17552S

sn-Glycero-3-phosphocholine-d9

sn-Glycero-3-phosphocholine-d₉ is the deuterium labeled sn-Glycero-3-phosphocholine. sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia[1][2].

HY-A0009S

Galanthamine-d3 hydrobromide

Galanthamine-d₃ (hydrobromide) is deuterium labeled Galanthamine (hydrobromide). Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3].

Cat. No.	Product Name		Classification